A Potential Notion on Alzheimer’s Disease: Nanotechnology as an Alternative Solution

Alzheimer’s disease is an eventually destroying disease of the overaged people featured by the dynamic and gradual brain erosion because of construction of extracellular plaques in the hippocampus. It is an undertreated and underrecognized disease that is becoming a major public health concern. From the study, it is known that production of plaques takes place twenty years back, before the commencement of clinical syndromes. As per report, in 2019, above 50 million people got into Alzheimer’s disease. Recent developments include improved clinical diagnostic guidelines and improved treatment of both cognitive disturbance and behavioral problems. Treatment majorly focus on cholinergic therapy has been clinically evaluated by different studies including randomized, double-blind, placebo-controlled, parallel-group studies measuring performance-based tests of cognitive function, activities of daily living, and behavior. The presence of extracellular plaques of insoluble β-amyloid peptide (Aβ) and neurofibrillary tangles (NFT) containing hyperphosphorylated tau protein (P-tau) in the neuronal cytoplasm is a remarkable pathophysiological cause in patients’ brains. The graph of increasing patients, suffering from Alzheimer’s disease, is being ascended. The outcome of this turn into fatal, deadly situation. So, there is a possibility of breaking down world economics and human strength. There is a different kind of organic as well as inorganic nanocomponent group, those have been pursued with satisfaction. By studying and researching over pathogenesis specifically, diagnosis of this AD as per its symptoms is possibly done. Treatment of this neurodisease is under processing. The experts are playing an extremely appreciable role for displacing this disease completely. The present review summarizes the pathophysiology and role of the nanoparticle in the diagnosis and treatment of AD.

[1]  A. Akter,et al.  Bioactive Compounds and Their Derivatives: An Insight into Prospective Phytotherapeutic Approach against Alzheimer's Disease , 2022, Oxidative medicine and cellular longevity.

[2]  Md. Jamal Hossain,et al.  Prospective multifunctional roles and pharmacological potential of dietary flavonoid narirutin. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  A. Mamun,et al.  Neuropharmacological Effects of Chassalia curviflora (Rubiaceae) Leaves in Swiss Albino Mice Model. , 2022, Archives of Razi Institute.

[4]  A. Rauf,et al.  Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  V. Tirth,et al.  Neuropharmacological and Antidiabetic Potential of Lannea coromandelica (Houtt.) Merr. Leaves Extract: An Experimental Analysis , 2022, Evidence-based complementary and alternative medicine : eCAM.

[6]  A. Akter,et al.  CNS depressant activities of Averrhoa carambola leaves extract in thiopental-sodium model of Swiss albino mice: implication for neuro-modulatory properties , 2022, Biologia.

[7]  G. Ashraf,et al.  Citrus limon L. (lemon) seed extract shows neuro-modulatory activity in an in vivo thiopental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration. , 2022, Journal of integrative neuroscience.

[8]  Dong-Dong Wu,et al.  Nanomedicine: A Promising Way to Manage Alzheimer’s Disease , 2021, Frontiers in Bioengineering and Biotechnology.

[9]  H. Zeng,et al.  Nanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends , 2021 .

[10]  M. Bilal,et al.  Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview , 2020 .

[11]  A. Navrotsky Nanoparticles , 2020, Managing Human and Social Systems.

[12]  K. Wei,et al.  Non-invasive focused ultrasound-based synergistic treatment of brain tumors , 2016 .

[13]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[14]  A. Mietelska-Porowska,et al.  Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction , 2014, International journal of molecular sciences.

[15]  R. Mayeux,et al.  Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[16]  M. S. Muthu,et al.  Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease. , 2011, Therapeutic delivery.

[17]  A. Di Stefano,et al.  Drug delivery strategies for Alzheimer's disease treatment , 2011, Expert opinion on drug delivery.

[18]  Chen Wang,et al.  Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[19]  Christine Vauthier,et al.  Methods for the Preparation and Manufacture of Polymeric Nanoparticles , 2009, Pharmaceutical Research.

[20]  Kostas Kostarelos,et al.  Designer adenoviruses for nanomedicine and nanodiagnostics. , 2009, Trends in biotechnology.

[21]  K. Jain,et al.  Nanomedicine: Application of Nanobiotechnology in Medical Practice , 2008, Medical Principles and Practice.

[22]  Yechezkel Barenholz,et al.  Liposome application: problems and prospects , 2001 .

[23]  F. Vögtle,et al.  Dendrimers: From Design to Application-A Progress Report. , 1999, Angewandte Chemie.

[24]  Junjie Liu,et al.  The Design and Application of Nanomaterials as Drug Carriers in Cancer Treatment. , 2019, Current medicinal chemistry.

[25]  Vincent M. Rotello,et al.  Nanoparticles: Building Blocks for Nanotechnology , 2010 .

[26]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.